Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in european patients with schizophrenia: a post hoc analysis of a global phase-3 double-blind randomized non-inferiority study

dc.contributor.author	Girón Hernández, César
dc.contributor.author	Han, Joong Hee
dc.contributor.author	Alberio, Roberta
dc.contributor.author	Singh, Arun
dc.contributor.author	García-Portilla González, María Paz
dc.contributor.author	Pompili, Maurizio
dc.contributor.author	Knight, R. Karl
dc.contributor.author	Richarz, Ute
dc.contributor.author	Gopal, Srihari
dc.contributor.author	Antunes, José
dc.date.accessioned	2023-11-07T09:58:13Z
dc.date.available	2023-11-07T09:58:13Z
dc.date.issued	2023
dc.identifier.citation	Neuropsychiatric Disease and Treatment, 19, p. 895-906 (2023); doi:10.2147/NDT.S400342
dc.identifier.uri	https://hdl.handle.net/10651/70072
dc.format.extent	p. 895-906
dc.language.iso	eng
dc.relation.ispartof	Neuropsychiatric Disease and Treatment
dc.rights	© 2023 The author(s). This work is published and licensed by Dove Medical Press Ltd
dc.rights	CC Reconocimiento - No Comercial 3.0
dc.rights.uri	http://creativecommons.org/licenses/by-nc/3.0/
dc.source	WOS:000970784500001
dc.title	Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in european patients with schizophrenia: a post hoc analysis of a global phase-3 double-blind randomized non-inferiority study
dc.type	journal article
dc.identifier.doi	10.2147/NDT.S400342
dc.relation.publisherversion	http://dx.doi.org/10.2147/NDT.S400342
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons